0
0
Big Pharma’s Embrace of Artificial Intelligence
During a time characterized by concerns surrounding the proliferation of Artificial Intelligence (AI), the pharmaceutical industry, notably companies like Moderna, stands out for its wholehearted adoption of AI technology. Moderna, in particular, has made a firm commitment to integrate AI into every facet of its organization, recognizing the transformative potential of this cutting-edge technology.
Moderna’s AI Integration Journey
Modern is determined to transition into a real-time AI company where AI becomes an integral component of all operations. The company has already experienced firsthand the benefits of AI and digitization in accelerating time-to-market and enhancing product quality. AI has proven instrumental in optimizing various aspects of Moderna’s value chain, spanning from drug design to clinical trial management, manufacturing processes, and commercial endeavors. The influence of AI extends beyond traditional boundaries, impacting functions such as customer service, finance, cybersecurity, and more. Moderna firmly believes that the seamless integration of AI into its operations is pivotal in pursuing its mission of delivering impactful mRNA medicines to the global populace, signaling just the inception of AI’s role in furthering the company’s objectives.
AI Leadership in Pharma Industry
Besides incorporating AI into their workflows, big pharma entities are positioning themselves as leaders in the AI domain. Notably, OpenAI recently appointed a board member from Pfizer to its board of directors, underscoring the industry’s commitment to driving innovation and progress through AI technologies.
Critique of Big Pharma’s AI Adoption
While big pharma’s enthusiasm for AI is undeniable, critics such as Dr. Jim Thorp from The Wellness Company’s Chief Medical Board caution against the potential dangers associated with the industry’s embrace of AI. Dr. Thorp highlights the historical readiness of big pharma to leverage untested and risky technologies for financial gains, raising concerns about the implications of unchecked AI integration in the pharmaceutical sector.
In summary, the pharmaceutical industry’s pivot towards AI heralds a new era of innovation and efficiency, albeit accompanied by apprehensions regarding the ethical and safety implications of this technological shift.
Image/Photo credit: source url
